Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Scott Kinlay, Ph.D., M.B.,B.S.

Concepts

This page shows the publications Scott Kinlay has written about Risk Assessment.
Connection Strength

0.170
  1. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. J Am Coll Cardiol. 2015 Sep 08; 66(10):1091-101.
    View in: PubMed
    Score: 0.033
  2. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015 Oct; 101(19):1569-76.
    View in: PubMed
    Score: 0.033
  3. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv. 2012 Jun; 5(3):372-80.
    View in: PubMed
    Score: 0.026
  4. Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv. 2011 Jun 01; 77(7):1055-62.
    View in: PubMed
    Score: 0.024
  5. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis. Catheter Cardiovasc Interv. 2011 Feb 01; 77(2):202-12.
    View in: PubMed
    Score: 0.024
  6. Clinical Outcomes and Cost Comparisons of Stent and Non-Stent Interventions in Infrainguinal Peripheral Artery Disease: Insights From the Excellence in Peripheral Artery Disease (XLPAD) Registry. J Invasive Cardiol. 2019 01; 31(1):1-9.
    View in: PubMed
    Score: 0.010
  7. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28; 2(1):e003103.
    View in: PubMed
    Score: 0.007
  8. Impact of door-to-activation time on door-to-balloon time in primary percutaneous coronary intervention for ST-segment elevation myocardial infarctions: a report from the Activate-SF registry. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):672-9.
    View in: PubMed
    Score: 0.007
  9. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension. Crit Pathw Cardiol. 2012 Mar; 11(1):40-2.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.